Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements by Kumar, Akash et al.
From genetics to genomics in prostate cancer 
research
Prostate cancer is diagnosed in more than 200,000 men 
and accounts for more than 30,000 fatalities in the USA 
every year [1]. The course of this disease is remarkably 
heterogeneous; some cancers remain asymptomatic for 
decades, while others rapidly metastasize to bone and 
other  tissues,  resulting  in  substantial  morbidity  and 
mortality. Although several genetic abnormalities have 
previously been identified in prostate cancer, including 
recurrent  rearrangements  involving  the  androgen-
regulated serine protease gene TMPRSS2 and members 
of  the  ETS  family  of  oncogenic  transcription  factors 
[1], a complete view of the prostate cancer genome has 
been lacking.
Major advances in DNA sequencing technology have 
recently enabled the exploration of the genetic under-
pinnings of cancer to an unprecedented level of detail. 
The  genomes  of  a  number  of  carcinomas,  including 
breast, lung and skin, have been sequenced (Table 1). 
These  studies  have  provided  fascinating  insights  into 
tumor biology, and have identified new leads for diag-
nosis  and  therapy  [2-4].  A  recent  Nature  article  by 
Berger and colleagues [1] details the first whole genome 
study  of  prostate  cancer.  The  work  builds  on  earlier 
findings  concerning  the  genetic  make-up  of  cancers 
and  highlights  aspects  that  appear  to  be  unique  to 
prostate tumors.
Relatively few point mutations in prostate cancer
Berger et al. [1] sequenced the genomes of seven high-
grade  aggressive  primary  prostate  cancers  and  corres-
ponding  normal  tissues  by  generating  approximately 
30-fold  genome  coverage  of  paired-end,  short-read 
sequencing  on  the  Illumina  platform.  After  mapping 
reads to the human reference genome, they found that 
each cancer genome possessed on average less than one 
somatic point mutation per megabase. This mutation rate 
is far lower than that previously seen in genomes of lung 
cancer  and  melanoma  (Table  1),  but  similar  to  that 
reported  for  breast  cancer  and  acute  myelogenous 
leukemia [2,3,5]. This pattern supports the notion that 
the  mechanisms  underlying  the  genesis  of  prostate 
cancer do not include common environmental carcino-
gens,  such  as  UV  radiation  in  melanoma  or  tobacco 
exposure  in  lung  cancer,  which  result  in  DNA  point 
mutations. The tumors had an average of 20 non-synony-
mous  (protein-changing)  substitutions  per  genome. 
Despite this relatively low mutation frequency, two genes, 
SPTA1 and SPOP, were recurrently mutated. SPOP has 
been  shown  to  interact  with  a  cell-death-associated 
protein  Daxx,  and  SPTA1  encodes  a  scaffold  protein 
involved  in  determining  cell  morphology.  The  specific 
mechanism by which these genes influence tumorigenesis 
remains to be established. Additionally, genes encoding 
proteins  involved  in  chromatin  remodeling,  antigen 
processing and heat shock were enriched for mutations, 
suggesting  that  these  pathways  may  be  relevant  in 
prostate tumorigenesis.
Abstract
A recent study involving whole genome sequencing 
of seven prostate cancers has provided the first 
comprehensive assessment of genomic changes 
that underlie this common malignancy. Point 
mutations were found to be infrequent but 
changes in chromosome structure were common. 
Rearrangements were linked to chromatin organization 
and associated with regions involved in transcription 
factor binding. Novel candidate prostate cancer genes 
were also identified, highlighting the importance of 
genome sequencing to identify oncogenic changes 
that are otherwise invisible to detection.
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Perhaps the most striking finding of the study by Berger 
et al. [1] concerned chromosomal alterations. Each cancer 
genome  contained  an  average  of  100  inter-  and  intra-
chromosomal  rearrangements.  Unsurprisingly,  three 
tumors  contained  rearrangements  involving  TMPRSS2 
and ERG (ETS-related gene) - an event previously reported 
to  occur  in  approximately  50%  of  primary  prostate 
carcino  mas  [6].  Of  great  interest,  the  investigators 
reported that a subset of rearrangements participated in 
a  ‘closed  chain’  pattern  in  which  multiple  inter-  and 
intrachromosomal  locations  exchange  breakpoint  arms 
without any loss in total genetic material (Figure 1). This 
pattern is distinct from one in which all breaks occur as 
reciprocal pairs, and the authors hypothesized that these 
events  may  be  due  to  the  simultaneous  disruption  of 
many co-localized chromosomes through a mechanism 
depicted in Figure 1. Genomic insults such as genotoxic 
damage produced by oxidative stress or ionizing radiation 
can  induce  DNA  breaks.  Subsequent  reshuffling  of 
chromosomal  material  may  help  to  drive  the  derange-
ment of many genes in parallel, the importance of which 
is bolstered by the recent findings of ‘chromo  thripsis’ or 
chromosomal  ‘shattering’  in  other  tumor  types  [7].  In 
contrast  to  the  events  seen  in  chromothripsis,  the  re-
arrange  ments  seen  in  these  prostate  cancers  affected 
multiple chromosomes at once. This pattern of rearrange-
ment  suggests  a  unique  mechanism  of  tumorigenesis 
within prostate cancer that may be associated with the 
known  influences  of  androgen  receptors  and  other 
regulators of gene expression.
A potential mechanism for rearrangements in 
hormone-driven cancers
It was noted by Berger et al. that closed chain rearrange-
ments  could  occur  if  chromosomes  were  spatially  co-
localized  before  rearrangement;  this  phenomenon  has 
been seen to occur through androgen receptor-induced 
‘transcription  hubs’  that  approximate  intra-  and 
intergenic  regions  under  common  regulatory  control 
(Figure  1).  The  investigators  looked  for  a  correlation 
between  the  locations  of  breakpoints  and  specific 
chromatin  marks  in  a  similar  TMPRSS2-ERG  fusion-
positive prostate cancer cell line and found a significant 
association between rearrangements in some TMPRSS2-
ERG fusion-positive tumors and open chromatin marks 
within the cell line [1].
In contrast, tumors without TMPRSS2-ERG alterations 
demonstrated  an  inverse  correlation  between  open 
chromatin  and  rearrangements,  indicating  that  these 
tumors  either  possess  different  patterns  of  chromatin 
organization from that of the cell line or preferentially 
rearrange  in  regions  of  closed  chromatin  [1].  Directly 
exploring  chromatin  structure  in  these  and  additional 
prostate  tumors,  and  measuring  the  overlap  between 
rearrangement  breakpoints  and  chromatin  state  may 
address this question.
Interestingly, Berger et al. [1] found that associations 
between  open  chromatin  and  rearrangements  also 
extended to breast cancer. Of 18 previously sequenced 
breast  cancer  samples,  16  exhibited  rearrangements 
that  overlapped  significantly  with  open  chromatin 
regions in the prostate cancer cell line as well as with 
estrogen  receptor  binding  sites.  This  pattern  was  not 
observed in lung cancers or melanoma, suggesting that 
it  may  be  most  relevant  to  hormone-driven  cancers, 
such  as  breast  and  prostate  cancers,  which  involve 
nuclear hormone receptors.
Candidate genes identified by whole genome 
sequencing
Whole genome sequencing also identified a set of novel 
genes  recurrently  disrupted  by  rearrangements  [1]. 
CADM2,  encoding  a  cellular  adhesion  molecule,  was 
rearranged  in  three  out  of  seven  tumors  studied  and 
rearrangements  were  seen  in  an  additional  six  out  of 
ninety  prostate  cancers  using  fluorescence  in  situ 
hybridization; as some rearrangements are too complex 
to  resolve  via  the  fluorescence  in  situ  hybridization 
method, this number is likely to be an underestimate. 
Similarly, the gene MAGI2 was recurrently affected by a 
copy-neutral rearrangement. MAGI2 is predicted to be 
Table 1. Genome alterations reported in published whole genome studies
	 Number	of	 Approximate	number	 Average	number	of	 Number	of	
	 tumors	 of	point	mutations	 non-synonymous	 rearrangements	
Tumor	type	 sequenced	 per	tumor	 mutations	per	tumor	 per	tumor	 Reference(s)
Lung (non-small-cell)  1  50,000  302  43  Lee et al. (2010) [8]
Melanoma  1  30,000  187  74  Pleasance et al. (2010) [2]
Lung (small-cell)  1  20,000  94  58  Pleasance et al. (2010) [3]
Breast  2  6,000  ~30  40  Ding et al. (2010) [4]; Shah et al. (2009) [9]
Prostate  7  4,000  20  ~100  Berger et al. (2011) [1] 
AML  1  1,000  8  ND  Mardis et al. (2009) [5] 
AML, acute myelogenous leukemia; ND, not determined.
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based on known interactions with PTEN. Additionally, 
mutations  in  PTEN  and  MAGI2  within  the  seven 
genomes  appear  to  be  mutually  exclusive,  further 
suggesting the involvement of the phosphatidylinositol 
3-kinase pathway as a driver of prostate carcinogenesis 
and  a  potentially  important  therapeutic  target.  As 
pointed out by the investigators, the fact that MAGI2 
was  disrupted  in  a  copy-neutral  manner  would  likely 
make it invisible to detection methods other than whole 
genome sequencing.
Implications for future prostate cancer research 
and treatment
The analysis of prostate cancer genomes highlights the 
utility of whole genome sequencing as a discovery tool in 
cancer.  Berger  et  al.  uncovered  novel  candidate  onco-
genes  using  this  approach,  identified  a  new  pattern  of 
chromosomal rearrangement and provided insights into 
the mechanisms by which rearrangements may arise. As 
the search for additional tumor-promoting and tumor-
suppressing  genes  continues,  this  work  exemplifies  the 
power  of  detailed  genomic  characterization  to  identify 
genes  disrupted  by  rearrangements  that  remain  un-
detectable by other approaches.
Additional  genomic  studies  of  prostate  cancers  are 
needed before its landscape and mechanisms of tumori-
genesis can be said to be well understood. The finding 
that  TMPRSS2  fusion  status  appears  to  influence  a 
tumor’s  pattern  of  chromosomal  rearrangement  is 
interest  ing.  It  will  be  important  to  characterize  the 
chromatin state of fusion-negative cells to help resolve 
the question of whether rearrangements in prostate cells 
have a tendency to occur in regions of open chromatin. 
Sequencing other types of tumors can determine whether 
the closed-chain patterns of rearrangements are present 
in other hormonally driven cancers or rather are unique 
to the prostate. In this regard, a comparison of estrogen-
receptor-positive  and  estrogen-receptor-negative  breast 
cancers may be informative. The Berger et al. study was 
not sufficiently large to rule out the possibility of new 
recurrently  mutated  genes  in  prostate  cancers,  and 
examining  the  genomes  of  additional  tumor  samples, 
especially  metastases,  may  uncover  new  therapeutic 
targets. However, the data do suggest that few specific 
genes  will  be  mutated  at  high  frequency  in  primary 
prostate cancers, and support the concept of pathway-
based  analyses  that  involve  assessing  alterations  in 
multiple  genes  that  each  may  influence  the  activation 
state of a given network. Lastly, it will be important to 
establish the functional relevance of both rearrangements 
and  point  mutations  identified  through  cause-effect 
experiments in preclinical models of prostate cancer.
The  future  of  cancer  management  will  likely  be 
governed by partitioning tumors into categories or classes 
based  on  their  constellation  of  mutations,  structural 
alterations and epigenetic states that control oncogenic 
pathways. Of critical clinical utility will be those genomic 
features that are prognostic and those that are amenable 
to  pharmacological  control.  In  the  simplest  case,  large 
subtypes of cancers are driven by single gene alterations 
that  are  directly  targetable,  such  as  the  Bcr-abl  fusion 
protein  of  chronic  myelogenous  leukemia,  and  others 
where mutations in a particular pathway are common, 
but  do  not  represent  the  single  accelerator  of  tumor 
growth,  such  as  EGFR  mutations  in  subsets  of  lung 
cancer.  More  likely,  as  emphasized  by  whole  genome 
analyses  of  epithelial  tumors,  cancers  such  as  those 
arising in the prostate are influenced by a collection of 
relatively rare mutations. Clinical assessment of tumors 
in this scenario will require methods to comprehensively 
assess  their  genomes  in  order  to  prescribe  the  most 
appropriate therapeutics. The diversity and complexity of 
tumor genomes coupled with the increasing affordability 
Figure	1.	Schematic	diagram	illustrating	the	hypothesized	mechanism	of	‘closed	chain’	rearrangement	formation. Chromatin structure 
or transcription factor binding causes certain chromosomes to be physically near each other. A genomic insult such as ionizing radiation may 
disrupt these co-localized chromosomes simultaneously. DNA repair machinery can incorrectly join chromosome fragments, resulting in chimeric 
chromosomes containing disruptions in multiple genes. The figure is adapted from Figure 2A in Berger et al. [1].
Co-localized chromosomes Breaks introduced across
multiple  chromosomes 
Incorrect rejoining of these
chromosomes results in formation
of ‘closed chain’ rearrangements  
Genomic insult
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indicate that these technologies will be increasingly used 
and  have  an  important  future  in  the  management  of 
cancer patients.
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